Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer

References

• Harris AL. Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2:38-47; PMID:11902584; http://dx.doi.org/10.1038/nrc704
   PubMed Web of Science ®Google Scholar
• Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 2008; 8:967-75; PMID:18987634; http://dx.doi.org/10.1038/nrc2540
   PubMed Web of Science ®Google Scholar
• Benito J, Zeng Z, Konopleva M, Wilson WR. Targeting hypoxia in the leukemia microenvironment. Int J Hematol Oncol 2013; 2:279-88; PMID:24490034; http://dx.doi.org/10.2217/ijh.13.32
   PubMedGoogle Scholar
• McKeown SR. Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. Br J Radiol 2014; 87:20130676; PMID:24588669; http://dx.doi.org/10.1259/bjr.20130676
   PubMed Web of Science ®Google Scholar
• Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26:225-39; PMID:17440684; http://dx.doi.org/10.1007/s10555-007-9055-1
   PubMed Web of Science ®Google Scholar
• Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, Dewhirst MW. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996; 56:941-43; PMID:8640781
   PubMed Web of Science ®Google Scholar
• Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996; 41:31-9; PMID:8961365; http://dx.doi.org/10.1016/S0167-8140(96)91811-3
   PubMed Web of Science ®Google Scholar
• Movsas B, Chapman JD, Hanlon AL, Horwitz EM, Greenberg RE, Stobbe C, Hanks GE, Pollack A. Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 2002; 60:634-9; PMID:12385924; http://dx.doi.org/10.1016/S0090-4295(02)01858-7
   PubMed Web of Science ®Google Scholar
• Subarsky P, Hill RP. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 2003; 20:237-50; PMID:12741682; http://dx.doi.org/10.1023/A:1022939318102
   PubMed Web of Science ®Google Scholar
• Coquelle A, Toledo F, Stern S, Bieth A, Debatisse M. A new role for hypoxia in tumor progression: induction of fragile site triggering genomic rearrangements and formation of complex DMs and HSRs. Mol Cell 1998; 2:259-65; PMID:9734364; http://dx.doi.org/10.1016/S1097-2765(00)80137-9
   PubMed Web of Science ®Google Scholar
• Mimura I, Tanaka T, Wada Y, Kodama T, Nangaku M. Pathophysiological response to hypoxia - from the molecular mechanisms of malady to drug discovery: epigenetic regulation of the hypoxic response via hypoxia-inducible factor and histone modifying enzymes. J Pharmacol Sci 2011; 115:453-8; PMID:21422728; http://dx.doi.org/10.1254/jphs.10R19FM
   PubMed Web of Science ®Google Scholar
• Graeber TG, Osmanian C, Jacks T, Housman DE, Koch SJ, Lowe SW, Giaccia AJ. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996; 379:88-91; PMID:8538748; http://dx.doi.org/10.1038/379088a0
   PubMed Web of Science ®Google Scholar
• Cosse JP, Michiels C. Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression. Anticancer Agents Med Chem 2008; 8:790-7; PMID:18855580; http://dx.doi.org/10.2174/187152008785914798
   PubMed Web of Science ®Google Scholar
• Phillips RJ, Mestas J, Gharaee-Kermani M, Burdick MD, Sica A, Belperio JA, Keane MP, Strieter RM. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem 2005; 280:473-81; PMID:15802268; http://dx.doi.org/10.1074/jbc.M500963200
   PubMed Web of Science ®Google Scholar
• Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004; 9(suppl 5):10-7; PMID:15591418; http://dx.doi.org/10.1634/theoncologist.9-90005-10
   PubMed Web of Science ®Google Scholar
• Gupta R, Chetty C, Bhoopathi P, Lakka S, Mohanam S, Rao JS. Downregulation of uPA/uPAR inhibits intermittent hypoxia induced epithelial-mesenchymal transition (EMT) in DAOY and D283 medulloblastoma cells. Int J Oncol 2011; 38:733-44; PMID:21181094
   PubMed Web of Science ®Google Scholar
• Taddei ML, Giannoni E, Comito G, Chiarugi P. Microenvironment and tumor cell plasticity: an easy way out. Cancer Lett 2013; 341:80-96; PMID:23376253; http://dx.doi.org/10.1016/j.canlet.2013.01.042
   PubMed Web of Science ®Google Scholar
• Duan JX, Jiao H, Kaizerman J, Stanton T, Evans JW, Lan L, Lorente G, Banica M, Jung D, Wang J, et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem 2008; 51:2412-20; PMID:18257544; http://dx.doi.org/10.1021/jm701028q
   PubMed Web of Science ®Google Scholar
• Meng F, Evans JW, Bhupathi D, Banica M, Lan L, Lorente G, Duan JX, Cai X, Mowday AM, Guise CP, et al. Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302. Mol Cancer Ther 2012; 11:740-51; PMID:22147748; http://dx.doi.org/10.1158/1535-7163.MCT-11-0634
   PubMed Web of Science ®Google Scholar
• Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, Duan JX, Ammons WS, Curd JG, Matteucci MD, et al. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res 2012; 18:758-70; PMID:22184053; http://dx.doi.org/10.1158/1078-0432.CCR-11-1980
   PubMed Web of Science ®Google Scholar
• Liu Q, Sun JD, Wang J, Ahluwalia D, Baker AF, Cranmer LD, Ferraro D, Wang Y, Duan JX, Ammons WS, et al. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother Pharmacol 2012; 69:1487-98; PMID:22382881; http://dx.doi.org/10.1007/s00280-012-1852-8
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer Stat 2008; 58:71-96; PMID:18287387
   PubMed Web of Science ®Google Scholar
• Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13; PMID:9196156
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25:1960-6; PMID:17452677; http://dx.doi.org/10.1200/JCO.2006.07.9525
   PubMed Web of Science ®Google Scholar
• Borad MJ, Reddy S, Uronis H, Sigal DS, Cohn AL, Schelman WR, Stephenson J, Chiorean EG, Rosen PJ, Ulrich B, et al. Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 (G+T) vs gemcitabine (G) alone in previously untreated patients with advanced pancreatic cancer. Cancer Res 2012; 72(Suppl 1); Abst. LB-121
   Google Scholar
• Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005; 11:4136-43; PMID:15930349; http://dx.doi.org/10.1158/1078-0432.CCR-04-2291
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369:1691-703.
   PubMed Web of Science ®Google Scholar
• Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, et al. Stromal disrupting effects of nab-paclitaxel in pancreatic cancer. Br J Cancer 2013; 109:926-33; PMID:23907428; http://dx.doi.org/10.1038/bjc.2013.415
   PubMed Web of Science ®Google Scholar
• Awasthi N, Zhang C, Schwarz AM, Hinz S, Wang C, Williams NS, Schwarz MA, Schwarz RE. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer. Carcinogenesis 2013; 34:2361-9; PMID:23803690; http://dx.doi.org/10.1093/carcin/bgt227
   PubMed Web of Science ®Google Scholar
• Weiss GJ, Infante JR, Chiorean EG, Borad MJ, Bendell JC, Molina JR, Tibes R, Ramanathan RK, Lewandowski K, Jones SF, et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res 2011; 17:2997-3004; PMID:21415214; http://dx.doi.org/10.1158/1078-0432.CCR-10-3425
   PubMed Web of Science ®Google Scholar
• Jung D, Lin L, Jiao H, Cai X, Duan JX, Matteucci M. Pharmacokinetics of TH-302: a hypoxically activated prodrug of bromo-isophosphoramide mustard in mice, rats, dogs and monkeys. Cancer Chemother Pharmother 2012; 69:643-54; PMID:21964906; http://dx.doi.org/10.1007/s00280-011-1741-6
   PubMed Web of Science ®Google Scholar
• Chu GC, Kimmelman AC, Hezel AF, DePinho RA. Stromal biology of pancreatic cancer. J Cell Biochem 2007; 101:887-907; PMID:17266048; http://dx.doi.org/10.1002/jcb.21209
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Von Hoff DD. Tumor-stroma interactions in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2007; 6:1186-97; PMID:17406031; http://dx.doi.org/10.1158/1535-7163.MCT-06-0686
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Von Hoff DD. Translational therapeutic opportunities in ductal adenocarcinoma of the pancreas. Clin Cancer Res 2012; 18:4249-56; PMID:22896691; http://dx.doi.org/10.1158/1078-0432.CCR-12-1327
   PubMed Web of Science ®Google Scholar
• Kallman RF, Dorie MJ. Tumor oxygenation and reoxygenation during radiation therapy: their importance in predicting tumor response. Int J Radiat Oncol Biol Phys 1986; 12:681-5; PMID:3700172; http://dx.doi.org/10.1016/0360-3016(86)90080-5
   PubMed Web of Science ®Google Scholar
• Dorie MJ, Kallman RF. Reoxygenation in the RIF-1 tumor after chemotherapy. Int J Radiat Oncol Biol Phys 1992; 24:295-9; PMID:1382047; http://dx.doi.org/10.1016/0360-3016(92)90684-A
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 2011; 29:4548-54; PMID:21969517; http://dx.doi.org/10.1200/JCO.2011.36.5742
   PubMed Web of Science ®Google Scholar
• Ide T, Kitajima Y, Miyoshi A, Ohtsuka T, Mitsuno M, Ohtaka K, Miyazaki K. The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling. Ann Surg Oncol 2007; 14:2600-7; PMID:17534684; http://dx.doi.org/10.1245/s10434-007-9435-3
   PubMed Web of Science ®Google Scholar
• Pizzi S, Porzionato A, Pasquali C, Guidolin D, Sperti C, Fogar P, Macchi V, De Caro R, Pedrazzoli S, Parenti A. Glucose transporter-1 expression and prognostic significance in pancreatic carcinogenesis. Histol Histopathol 2007; 24:175-8540.
   Web of Science ®Google Scholar
• Soffietti R, Trevisan E, Rudà R. Neurologic complications of chemotherapy and other newer and experimental approaches. Handb Clin Neurol 2014; 121:1199-218; PMID:24365412
   PubMedGoogle Scholar
• Hureaux J, Lagarce F, Gagnadoux F, Rousselet MC, Moal V, Urban T, Benoit JP. Toxicological study and efficacy of blank and paclitaxel-loaded lipid nanocapsules after i.v. administration in mice. Pharm Res 2010; 27:421-30; PMID:20054705; http://dx.doi.org/10.1007/s11095-009-0024-y
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007; 49:928-40; PMID:17066459; http://dx.doi.org/10.1002/pbc.21078
   PubMed Web of Science ®Google Scholar
• Chaplan SR, Pogrel JW, Yaksh TL. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia. J Pharmacol Exp Ther 1994; 269:1117-23; PMID:8014856
   PubMed Web of Science ®Google Scholar
• Poree LR, Guo TZ, Kingery WS, Maze M. The analgesic potency of dexmedetomidine is enhanced after nerve injury: a possible role for peripheral alpha2-adrenoceptors. Anesth Analg 1998; 87:941-8; PMID:9768799
   PubMed Web of Science ®Google Scholar